This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lane, R. M. Search for Related Content PubMed PubMed Citation Articles by Lane, R. M. Social Bookmarking                         What's this?

SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment

Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA

The selective serotonin reuptake inhibitors (SSRIs) may occasionally induce extrapyramidal side-effects (EPS) and/or akathisia.This maybe a consequence of serotonergically-mediated inhibition of the dopaminergic system. Manifestations of these effects in patients may depend on predisposing factors such as the presence of psychomotor disturbance, a previous history of drug-induced akathisia and/or EPS, concurrent antidopaminergic and/or serotonergic therapy, recent monoamine oxidase inhibitor discontinuation, comorbid Parkinson's disease and possibly deficient cytochrome P450 (CYP) isoenzyme status. There is increasing awareness that there may be a distinct form of melancholic or endogenous depression with neurobiological underpinnings similar to those of disorders of the basal ganglia such as Parkinson's disease. Thus, it is not surprising that some individuals with depressive disorders appear to be susceptible to developing drug-induced EPS and/or akathisia. In addition, the propensity for the SSRIs to induce these effects in individual patients may vary within the drug class depending, for example, on their selectivity for serotonin relative to other monoamines, affinity for the 5-HT_2C receptor, pharmacokinetic drug interaction potential with concomitantly administered neuroleptics and potential for accumulation due to a long half-life. The relative risk of EPS and akathisia associated with SSRIs have yet to be clearly established. The potential risks may be reduced by avoiding rapid and unnecessary dose titration. Furthermore, early recognition and appropriate management of EPS and/or akathisia is required to prevent the impact of these effects on patient compliance and subjective well-being. It is important that the rare occurrence of EPS in patients receiving SSRIs does not preclude their use in Parkinson's disease where their potentially significant role requires more systematic evaluation.

Key Words: akathisia • basal ganglia • CYP2D6 • dopamine • extrapyramidal side-effects • SSRIs • serotonin syndrome

Journal of Psychopharmacology, Vol. 12, No. 2, 192-214 (1998)
DOI: 10.1177/026988119801200212


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. I. Sinclair, D. M. Christmas, S. D. Hood, J. P. Potokar, A. Robertson, A. Isaac, S. Srivastava, D. J. Nutt, and S. J. C. Davies Antidepressant-induced jitteriness/anxiety syndrome: systematic review The British Journal of Psychiatry, June 1, 2009; 194(6): 483 - 490. [Abstract] [Full Text] [PDF]

				R. Hieber, T. Dellenbaugh, and L. A. Nelson Role of Mirtazapine in the Treatment of Antipsychotic-Induced Akathisia Ann. Pharmacother., June 1, 2008; 42(6): 841 - 846. [Abstract] [Full Text] [PDF]

				I. Back and M. Taubert A case report : Akathisia and an unusual symptomatic treatment Palliative Medicine, December 1, 2007; 21(8): 713 - 715. [Abstract] [PDF]

				S. Ranjan, P. S Chandra, S. K Chaturvedi, S. C Prabhu, and A. Gupta Atypical Antipsychotic-Induced Akathisia with Depression: Therapeutic Role of Mirtazapine Ann. Pharmacother., April 1, 2006; 40(4): 771 - 774. [Abstract] [Full Text] [PDF]

				R. BALDWIN, S. JEFFRIES, A. JACKSON, C. SUTCLIFFE, N. THACKER, M. SCOTT, and A. BURNS Neurological findings in late-onset depressive disorder: comparison of individuals with and without depression The British Journal of Psychiatry, April 1, 2005; 186(4): 308 - 313. [Abstract] [Full Text] [PDF]

				L. Hansen, R. M. Jones, and D. Kingdon No Association between Akathisia or Parkinsonism and Suicidality in treatment-Resistant Schizophrenia J Psychopharmacol, September 1, 2004; 18(3): 384 - 387. [Abstract] [PDF]

				D. HEALY and D. CATTELL Interface between authorship, industry and science in the domain of therapeutics The British Journal of Psychiatry, July 1, 2003; 183(1): 22 - 27. [Abstract] [Full Text] [PDF]

				M. POYUROVSKY and A. WEIZMAN Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem The British Journal of Psychiatry, July 1, 2001; 179(1): 4 - 8. [Full Text] [PDF]

				D. Healy and R. Tranter Pharmacological stress diathesis syndromes J Psychopharmacol, May 1, 1999; 13(3): 287 - 290. [Abstract] [PDF]

				B. J. Stanford and S. C. Stanford Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol, May 1, 1999; 13(3): 313 - 317. [Abstract] [PDF]